Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ulcerative Colitis - Overview
Ulcerative Colitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Ulcerative Colitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ulcerative Colitis - Companies Involved in Therapeutics Development
Ulcerative Colitis - Drug Profiles
Ulcerative Colitis - Dormant Projects
Ulcerative Colitis - Discontinued Products
Ulcerative Colitis - Product Development Milestones
Featured News & Press Releases
Jul 27, 2022: EC grants approval for AbbVie’s Rinvoq to treat ulcerative colitis in adults
Jul 21, 2022: Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz (adalimumab-adaz) high concentration formulation (HCF)
Jul 18, 2022: Prometheus Biosciences completes enrollment of the ARTEMIS-UC cohort 1 phase 2 study in ulcerative colitis
Jul 07, 2022: Biora Therapeutics announces successful completion of second device performance study in human subjects for its targeted therapeutics platform
Jul 06, 2022: Applied Molecular Transport announces top-line phase 2 results from MARKET combition trial of oral AMT-101 in patients with moderate-to-severe ulcerative colitis
Jul 06, 2022: Applied Molecular Transport to report top-line phase 2 results from MARKET combition trial of oral AMT-101 in patients with moderate-to-severe ulcerative colitis
Jul 04, 2022: Innovent Phase II ulcerative colitis antibody trial doses first subject
Jun 20, 2022: EMA accepts Sandoz’s application for high concentration of biosimilar
Jun 08, 2022: Prometheus Biosciences provides enrollment update in APOLLO-CD and ARTEMIS-UC global phase 2 Studies
May 31, 2022: Biora Therapeutics shares presentation of patient data establishing correlation between drug levels in colon and patient outcomes in ulcerative colitis
May 27, 2022: The lancet publishes results from phase 3 induction and maintence programs evaluating Upadacitinib (RINVOQ) in ulcerative colitis
May 24, 2022: InDex Pharmaceuticals to exhibit at Digestive Disease Week
May 24, 2022: Pfizer presents ELEVATE pivotal findings demonstrating etrasimod’s potentially best-in-class profile in ulcerative colitis
May 24, 2022: Fifty percent of patients with ulcerative colitis treated with Mirikizumab achieved clinical remission at one year in Lilly’s pivotal phase 3 study
May 24, 2022: Alvotech clinical study results demonstrate therapeutic equivalence between biosimilar candidate AVT04 and reference product Stelara
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Ulcerative Colitis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Ulcerative Colitis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Ulcerative Colitis - Dormant Projects, 2022
Ulcerative Colitis - Discontinued Products, 2022